Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.31 +1.4%	$5.79	$4.02 ▼ $15.10	$342.49M	2.1	1.78 million shs	877,865 shs
IRWD Ironwood Pharmaceuticals	$0.70 +10.1%	$0.71	$0.53 ▼ $7.11	$113.08M	0.24	2.60 million shs	1.73 million shs
RIGL Rigel Pharmaceuticals	$19.36 +1.0%	$19.23	$7.48 ▼ $29.82	$346.01M	1.29	220,717 shs	142,458 shs
ZBIO Zenas BioPharma	$9.31 -3.8%	$10.10	$5.83 ▼ $26.25	$389.48M	N/A	192,963 shs	130,927 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	0.00%	-4.58%	-9.12%	+10.75%	+4.08%
IRWD Ironwood Pharmaceuticals	0.00%	+4.55%	+7.11%	-50.44%	-87.74%
RIGL Rigel Pharmaceuticals	0.00%	-9.11%	-3.78%	-4.16%	+114.47%
ZBIO Zenas BioPharma	0.00%	-17.76%	-18.90%	+11.76%	+930,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent Biosolutions	4.4408 of 5 stars	3.5	2.0	4.6	2.6	2.5	1.3
IRWD Ironwood Pharmaceuticals	4.3705 of 5 stars	4.1	3.0	3.4	1.1	0.8	1.9
RIGL Rigel Pharmaceuticals	3.7192 of 5 stars	3.2	2.0	0.0	3.5	1.7	3.1
ZBIO Zenas BioPharma	1.5059 of 5 stars	3.5	0.0	0.0	1.7	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	3.00	Buy	$14.33	127.26% Upside
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	584.51% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	88.02% Upside
ZBIO Zenas BioPharma	3.00	Buy	$36.67	293.84% Upside

Current Analyst Ratings Breakdown

Latest IRWD, ZBIO, RIGL, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ZBIO Zenas BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$35.00
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
4/16/2025	IRWD Ironwood Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/15/2025	IRWD Ironwood Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00 ➝ $1.00
4/15/2025	IRWD Ironwood Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $0.70
4/14/2025	IRWD Ironwood Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform ➝ Market Perform	$3.00 ➝ $1.00
4/14/2025	IRWD Ironwood Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
4/1/2025	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/21/2025	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/20/2025	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$35.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$1.04B	0.33	$1.92 per share	3.28	$8.91 per share	0.71
IRWD Ironwood Pharmaceuticals	$351.41M	0.32	$0.05 per share	14.13	($1.88) per share	-0.37
RIGL Rigel Pharmaceuticals	$179.28M	1.93	$1.08 per share	17.94	$0.19 per share	101.89
ZBIO Zenas BioPharma	$5M	77.89	N/A	N/A	$7.48 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.05	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	$880K	-$0.20	N/A	2.80	N/A	-9.89%	-1.87%	-3.93%	8/6/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$2.07	9.35	18.44	N/A	18.31%	-655.26%	24.47%	8/5/2025 (Estimated)
ZBIO Zenas BioPharma	-$156.99M	-$3.55	N/A	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)

Latest IRWD, ZBIO, RIGL, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ZBIO Zenas BioPharma	-$1.15	-$0.80	+$0.35	-$0.80	$5.00 million	$10.00 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.20	6.32	3.51
IRWD Ironwood Pharmaceuticals	N/A	3.34	3.34
RIGL Rigel Pharmaceuticals	2.42	2.20	2.13
ZBIO Zenas BioPharma	N/A	6.47	6.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
IRWD Ironwood Pharmaceuticals	N/A
RIGL Rigel Pharmaceuticals	66.23%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	1.20%
IRWD Ironwood Pharmaceuticals	12.70%
RIGL Rigel Pharmaceuticals	9.48%
ZBIO Zenas BioPharma	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
IRWD Ironwood Pharmaceuticals	220	161.82 million	141.27 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.18 million	Optionable
ZBIO Zenas BioPharma	N/A	41.83 million	34.93 million	N/A

IRWD, ZBIO, RIGL, and EBS Headlines

Recent News About These Companies

ZBIO DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 ...

June 17 at 10:15 AM | stockhouse.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 17 at 10:00 AM | prnewswire.com

Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)

June 16, 2025 | accessnewswire.com

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 16, 2025 | globenewswire.com

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

June 16, 2025 | globenewswire.com

June 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky

June 16, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 16, 2025 | accessnewswire.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

June 16, 2025 | businesswire.com

Securities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025

June 16, 2025 | accessnewswire.com

ZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

June 16, 2025 | prnewswire.com

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Zenas BioPharma, Inc. (ZBIO) Investors of June 16, 2025 Deadline

June 16, 2025 | accessnewswire.com

FINAL REMINDER ZBIO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Zenas BioPharma, Inc. Investors to Participate in the Class Action Lawsuit

June 16, 2025 | accessnewswire.com

June 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIO

June 16, 2025 | prnewswire.com

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors - Lead Plaintiff Deadline June 16, 2025

June 16, 2025 | accessnewswire.com

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

June 16, 2025 | prnewswire.com

Securities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025

June 15, 2025 | accessnewswire.com

ZBIO IMPORTANT DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by The Firm - ZBIO

June 15, 2025 | accessnewswire.com

Zenas BioPharma, Inc. (ZBIO) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before June 16, 2025

June 15, 2025 | accessnewswire.com

Zenas BioPharma, Inc. (ZBIO) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of June 16, 2025 Deadline

June 15, 2025 | accessnewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

June 15, 2025 | prnewswire.com

Zenas Biopharma Inc (NASDAQ:ZBIO) Shares Sold by Wellington Management Group LLP

June 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD, ZBIO, RIGL, and EBS Company Descriptions

Emergent Biosolutions NYSE:EBS

$6.31 +0.09 (+1.40%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$6.36 +0.05 (+0.76%)

As of 06/18/2025 07:08 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.70 +0.06 (+10.12%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.68 -0.02 (-2.69%)

As of 06/18/2025 07:37 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Rigel Pharmaceuticals NASDAQ:RIGL

$19.36 +0.20 (+1.04%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$19.36 0.00 (-0.03%)

As of 06/18/2025 07:15 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Zenas BioPharma NASDAQ:ZBIO

$9.31 -0.37 (-3.82%)

As of 06/18/2025 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time